PT - JOURNAL ARTICLE AU - Felix Dietlein AU - Carsten Kobe AU - Stephan Neubauer AU - Matthias Schmidt AU - Simone Stockter AU - Thomas Fischer AU - Klaus Schomäcker AU - Axel Heidenreich AU - Boris D. Zlatopolskiy AU - Bernd Neumaier AU - Alexander Drzezga AU - Markus Dietlein TI - PSA-stratified performance of <sup>18</sup>F- and <sup>68</sup>Ga-labeled tracers in PSMA-PET imaging of patients with biochemical recurrence of prostate cancer AID - 10.2967/jnumed.116.185538 DP - 2016 Nov 01 TA - Journal of Nuclear Medicine PG - jnumed.116.185538 4099 - http://jnm.snmjournals.org/content/early/2016/11/30/jnumed.116.185538.short 4100 - http://jnm.snmjournals.org/content/early/2016/11/30/jnumed.116.185538.full AB - Purpose: Several studies outlined the sensitivity of 68Ga-labeled PET tracers against the prostate-specific membrane antigen (PSMA) for localization of relapsed prostate cancer in patients with renewed increase in the prostate-specific antigen (PSA), commonly referred to as biochemical recurrence. Labeling of PSMA tracers with 18F offers numerous advantages, including improved image resolution, longer half-life and increased production yields. The aim of this study was to assess the PSA-stratified performance of the 18F-labeled PSMA tracer 18F-DCFPyL and the 68Ga-labeled reference 68Ga-PSMA-HBED-CC. Methods: We examined 191 consecutive patients with biochemical recurrence according to standard acquisition protocols with 18F-DCFPyL (N = 62, 269.8 MBq, PET scan at 120 minutes p.i.) or 68Ga-PSMA-HBED-CC (N = 129, 158.9 MBq, 60 minutes p.i.). We determined PSA-stratified sensitivity rates for both tracers and corrected our calculations for Gleason scores using iterative matched-pair analyses. As an orthogonal validation, we directly compared tracer distribution patterns in a separate cohort of 25 patients, sequentially examined with both tracers. Results: After prostatectomy (N = 106), the sensitivity of both tracers was significantly associated with absolute PSA levels (P = 4.3x10-3). Sensitivity increased abruptly, when PSA values exceeded 0.5µg/L (P = 2.4x10-5). For PSA &lt;3.5µg/L, most relapses were diagnosed at a still limited stage (P = 3.4x10-6). For PSA of 0.5-3.5µg/L, PSA-stratified sensitivity was 88% (15/17) for 18F-DCFPyL and 66% (23/35) for 68Ga-PSMA-HBED-CC. This significant difference was preserved in the Gleason-matched-pair analysis. Outside of this range, sensitivity was comparably low (PSA &lt;0.5µg/L) or high (PSA &gt;3.5µg/L). After radiotherapy (N = 85), tracer sensitivity was largely PSA-independent. In the 25 patients examined with both tracers, distribution patterns of 18F-DCFPyL and 68Ga-PSMA-HBED-CC were strongly comparable (P = 2.71x10-8). However, in 36% of the PSMA-positive patients we detected additional lesions on the 18F-DCFPyL scan (P = 3.7x10-2). Conclusion: Our data suggest that 18F-DCFPyL is non-inferior to 68Ga-PSMA-HBED-CC, while offering the advantages of 18F-labeling. Our results indicate that imaging with 18F-DCFPyL may even exhibit improved sensitivity in localizing relapsed tumors after prostatectomy for moderately increased PSA levels. Although the standard acquisition protocols, used for 18F-DCFPyL and 68Ga-PSMA-HBED-CC in this study, stipulate different activity doses and tracer uptake times after injection, our findings provide a promising rationale for validation of 18F-DCFPyL in future prospective trials.